Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)

v3.5.0.2
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Jun. 30, 2016
Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities $ 5,700    
Advanced Cell Diagnostics (ACD) [Member]      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory 12,800    
Certificates of Deposit [Member] | CHINA      
Payments to Acquire Available-for-sale Securities 5,200    
ChemoCentryx, Inc (CCXI) [Member]      
Available-for-sale Equity Securities, Gross Unrealized Gain 9,900    
Available-for-sale Equity Securities, Amortized Cost Basis 29,500   $ 29,500
Available-for-sale Securities 52,400   31,600
Payments to Acquire Available-for-sale Securities 6,836  
Inventory Valuation Reserves $ 24,000   $ 24,000